NEW Study Released About the COVID-19 PILL From MERCK: Molnupiravir - What you NEED to KNOW episode artwork

EPISODE · Oct 13, 2021 · 20 MIN

NEW Study Released About the COVID-19 PILL From MERCK: Molnupiravir - What you NEED to KNOW

from Baktari MD · host Jonathan Baktari MD

Due to their recent findings, Merck and partner Ridgeback Biotherapeutics asked the U.S. Food and Drug Administration to grant emergency use authorization for their new drug, Molnupiravir, to treat adults with mild-to-moderate COVID-19 who are at risk for severe disease or hospitalization. In today's episode, I use my biochemistry background along with my many years of experience in the medical field to dissect their study, what it could mean for the future of the Coronavirus Pandemic and explain just how Molnupiravir works. Is the COVID-19 pill a replacement to the mRNA vaccines? Is their a risk of Molnupiravir affecting your own DNA? Could this pill dramatically reduce the deaths from COVID-19? I go over all of these questions and more.  Links to the resources I discuss in this episode:Merck and Ridgeback’s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study:https://www.merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderat/β-D-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells:https://academic.oup.com/jid/article/224/3/415/6272009?login=trueLetter to the Editor in Response to Zhou et al:https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiab362/6319402Thank you for joining me on another episode of Baktari MD! Do you have a question regarding our healthcare system? Please leave your question in the comments below so I can make an episode about it. Also, I’d love to hear any suggestions you may have for future content.For more information, please visit: https://jonathanbaktarimd.com/Sign up for my newsletter here: https://ns.jonathanbaktarimd.com/SOCIAL:Facebook: https://www.facebook.com/baktarimdInstagram: https://www.instagram.com/baktarimd/Twitter: https://twitter.com/BaktariMDLinkedIn: https://www.linkedin.com/in/jonathan-baktarimd/YouTube: https://www.youtube.com/baktarimdDisclaimer: All information discussed or provided by Jonathan Baktari, M.D. (“Dr. Baktari”) and/or his affiliates/guests are for educational purposes only. The information discussed and provided is not a substitute for professional medical advice, diagnosis, or treatment.  Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical concern or condition. Never disregard professional medical advice or delay in seeking it because of any information discussed or provided by Dr. Baktari or his affiliates/guests!  If you think you may have a medical emergency, call 911 immediately.  All information concerning hospitals, physicians, insurers, and other healthcare-related companies is based on Dr. Baktari’s observations of the healthcare industry as a whole and do not reflect on any specific hospital, physician, insurer, or other healthcare-related company.

Episode metadata supplied by the publisher feed · Published Oct 13, 2021

Embed this episode

Due to their recent findings, Merck and partner Ridgeback Biotherapeutics asked the U.S. Food and Drug Administration to grant emergency use authorization for their new drug, Molnupiravir, to treat adults with mild-to-moderate COVID-19 who are at risk for severe disease or hospitalization. In today's episode, I use my biochemistry background along with my many years of experience in the medical field to dissect their study, what it could mean for the future of the Coronavirus Pandemic ...

Distinct summary based on available episode metadata or transcript content.

NOW PLAYING

NEW Study Released About the COVID-19 PILL From MERCK: Molnupiravir - What you NEED to KNOW

0:00 20:25

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Baktari MD?

This episode is 20 minutes long.

When was this Baktari MD episode published?

This episode was published on October 13, 2021.

Is there a transcript available for this episode?

Yes, a full transcript is available for this episode. You can read the complete transcript on the episode page.

Can I download this Baktari MD episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!